01 1Cambrex Corporation
01 1RIFAXIMIN
01 1U.S.A
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2017-10-27
Pay. Date : 2016-09-27
DMF Number : 31114
Submission : 2016-11-04
Status : Active
Type : II
20
Cambrex Profarmaco Milano Srl, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for Cambrex is an innovative life sciences company with a refreshingly human approach.
One of their notable products is RIFAXIMIN, with a corresponding US DMF Number 31114.
Remarkably, this DMF maintains an Active status since its submission on November 04, 2016, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of October 27, 2017, and payment made on September 27, 2016, indicating their dedication to facilitating drug approvals, Categorized as Type II
